Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen YHLO Biotech CoSHSE:688575 -5.44%64 Return-on-Tangible-Equity is 2.83% as of Mar. 2026, which is 82% below its 10-year median of 15.61. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥14.66 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks worse than 56.73% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shenzhen YHLO Biotech Co's annualized net income for the quarter that ended in Mar. 2026 was ¥72 Mil. Shenzhen YHLO Biotech Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥2,541 Mil. Therefore, Shenzhen YHLO Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 2.83%.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688575'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.92 Med: 15.61 Max: 55.99
Current: 1.23
During the past 9 years, Shenzhen YHLO Biotech Co's highest Return-on-Tangible-Equity was 55.99%. The lowest was 0.92%. And the median was 15.61%.
SHSE:688575's Return-on-Tangible-Equity is ranked worse than 56.73% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs SHSE:688575: 1.23
Shenzhen YHLO Biotech Co (SHSE:688575) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shenzhen YHLO Biotech Co Return-on-Tangible-Equity Related Terms
Shenzhen YHLO Biotech Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co Return-on-Tangible-Equity Chart
SHSE:688575 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.83% mean?
Shenzhen YHLO Biotech Co (SHSE:688575) has a Return-on-Tangible-Equity of 2.83% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is 82% below median its historical median of 15.61. Over the past decade, Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity has ranged from 0.92 to 55.99. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #430 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 56.7%.
Is Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity too high?
Shenzhen YHLO Biotech Co's current Return-on-Tangible-Equity of 2.83% is 82% below median its 10-year median of 15.61. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 55.99. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. Shenzhen YHLO Biotech Co's value of 2.83% is 30.2% below this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #430 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #430 out of 758 companies for Return-on-Tangible-Equity. This places Shenzhen YHLO Biotech Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.06. Shenzhen YHLO Biotech Co's value of 2.83% is 30.2% below this benchmark. Historically, Shenzhen YHLO Biotech Co's own Return-on-Tangible-Equity has ranged from 0.92 to 55.99 over the past decade. While the company's 10-year median is 15.61 vs. the industry median of 4.06, Shenzhen YHLO Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current Return-on-Tangible-Equity of 2.83% is 30.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current Return-on-Tangible-Equity is 2.83%, which is 82% below median its own 10-year median of 15.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.66, compared to a current price of ¥8.52 — trading 41.9% below its estimated fair value. The current Return-on-Tangible-Equity is 2.83%, which is 82% below median its 10-year median of 15.61 and 30.2% below the Medical Devices & Instruments industry median of 4.06. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current Return-on-Tangible-Equity is 2.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥8.52 is trading 41.9% below its estimated GF Value™ of ¥14.66.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
Return-on-Tangible-Equity: 2.83% (82% below median its 10-year median of 15.61)
GF Value™: ¥14.66 vs. price of ¥8.52 (41.9% below fair value)
Industry Position: 30.2% below the Medical Devices & Instruments median (#430 of 758)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
